740 results on '"Tumani, H"'
Search Results
2. Konsensuspapier zum Einsatz der therapeutischen Apherese in der Neurologie
3. Optical coherence tomography-based assessment of retinal vascular pathology in cerebral small vessel disease
4. S1 guidelines “lumbar puncture and cerebrospinal fluid analysis” (abridged and translated version)
5. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis
6. Author Correction: Serum GFAP as a biomarker for disease severity in multiple sclerosis
7. Epidemiology of amyotrophic lateral sclerosis in Southern Germany
8. Strategien der Liquorbefundung – integrierter Befundbericht
9. Liquordiagnostik bei Multipler Sklerose
10. Serum GFAP as a biomarker for disease severity in multiple sclerosis
11. MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature
12. Monitoring von Blutparametern unter verlaufsmodifizierender MS-Therapie: Substanzspezifische Relevanz und aktuelle Handlungsempfehlungen
13. Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview
14. Intrathecal immunoglobulin synthesis in patients with symptomatic epilepsy and epilepsy of unknown etiology (‘cryptogenic’)
15. Aktuelles zur Therapieumstellung bei Multipler Sklerose
16. Effects of Repeated Intrathecal Triamcinolone-Acetonide Application on Cerebrospinal Fluid Biomarkers of Axonal Damage and Glial Activity in Multiple Sclerosis Patients
17. Glutamine Synthetase in Cerebrospinal Fluid is Brain-Derived and Elevated in Neurodegenerative Diseases
18. CXCL13 als Biomarker der akuten Neuroborreliose: Überprüfung des prädiktiven Wertes in der klinischen Routine
19. 6-sulpho LacNAc+ dendritic cells accumulate in various inflammatory, but not ischaemic conditions of the central nervous system
20. Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: Identification of subgroups with immune responses and blood–CSF barrier dysfunction
21. An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels
22. Natalizumab-associated cerebellar PML: a case report on how to slow down IRIS
23. Stellenwert der Liquordiagnostik bei neuropsychiatrischen Erkrankungen
24. Aktuelle Liquordiagnostik bei erregerbedingten Krankheiten
25. Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
26. Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview
27. Central inflammation versus peripheral regulation in multiple sclerosis
28. Liquordiagnostik bei CT-negativer Subarachnoidalblutung
29. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage
30. Retinal single layer analysis with optical coherence tomography as a possible neurodegeneration marker in Parkinsonʼs disease: 235
31. Patientin mit organischem Psychosyndrom und neurologischen Herdzeichen unter Immunsuppression
32. Gender-specificities in Alzheimer's disease and mild cognitive impairment
33. Hochdosiskortisontherapie und Kognition
34. Proteome analysis of cerebrospinal fluid in Guillain–Barré syndrome (GBS)
35. Narcolepsy: Increased L–PGDS (β–trace) levels correlate with excessive daytime sleepiness but not with cataplexy
36. Isolated blood–cerebrospinal fluid barrier dysfunction: prevalence and associated diseases
37. Optical coherence tomography does not support optic nerve involvement in amyotrophic lateral sclerosis
38. Disease-Specific Cerebrospinal Fluid Investigations
39. Routine Cerebrospinal Fluid (CSF) Analysis
40. Impact of serum storage conditions on microRNA stability
41. A novel presenilin1 mutation (Q223R) associated with early onset Alzheimerʼs disease, dysarthria and spastic paraparesis and decreased Abeta levels in CSF
42. Diagnosis of cerebral toxoplasmosis by detection of Toxoplasma gondii tachyzoites in cerebrospinal fluid
43. CSF PROTEIN BIOMARKERS FOR PROXIMAL AXONAL DAMAGE IMPROVE PROGNOSTIC ACCURACY IN THE ACUTE PHASE OF GUILLAIN-BARRÉ SYNDROME
44. EFNS guidelines on disease-specific CSF investigations
45. C.1 Von der klinischen Diagnose zum Liquorbefund
46. A.3 Anatomie und Physiologie des Liquorsystems
47. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options
48. Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica
49. MxA protein – an interferon beta biomarker in primary progressive multiple sclerosis patients
50. Early diagnosis of rhinocerebral mucormycosis by cerebrospinal fluid analysis and determination of 16s rRNA gene sequence
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.